VDPV and VAPP

Vaccine-Associated Paralytic Poliomyelitis

Definition And Diagnostic Criteria

• Vaccine-associated paralytic poliomyelitis represents paralytic polio occurring in vaccine recipients or close contacts.
• Causative agent involves poliovirus strain genetically altered in host intestine from original attenuated vaccine strain.
• Diagnosis requires acute flaccid paralysis demonstrating residual paralysis lasting minimum 60 days.
• Paralysis manifests in oral poliovirus vaccine recipients between 4 and 40 days following administration.
• Paralysis manifests in known vaccine contacts between 7 and 60 to 75 days following administration.
• Laboratory confirmation requires isolation of vaccine-related poliovirus from stool samples without wild poliovirus isolation.

Epidemiology And Incidence

• Clinical presentation remains indistinguishable from paralytic poliomyelitis caused by wild virus.
• Global incidence ranges from 2 to 4 cases per million births annually.
• Highest risk follows initial oral vaccine dose, occurring in 1 per 2.9 million administered doses.
• Initial dose recipients and contacts carry 6.6-fold higher risk compared to subsequent dose recipients.
• Industrialized nations report cases primarily in early infancy during initial dosing.
• Developing nations report gradual decline across subsequent doses, concentrating cases among children aged 1 to 4 years.
• Type 3 poliovirus causes 42 percent of cases, followed by type 2 causing 26 percent, type 1 causing 20 percent, and mixed strains causing 15 percent.
• Indian burden remains obscure due to classification under non-polio acute flaccid paralysis.
• Indian risk remains comparatively lower due to maternal antibodies, birth dose administration, and lower vaccine uptake rates.

Pathophysiology

• Sabin vaccine strains demonstrate genetic instability during replication in human gut.
• Attenuated virus regains virulence through reversion of key attenuating mutations.
• Lower immune responsiveness to oral vaccine and high prevalence of maternal antibodies facilitate prolonged replication.
• Simultaneous administration of multiple serotypes causes interference, allowing dominant serotypes prolonged replication time.

Vaccine-Derived Polioviruses

Definition And Genetic Basis

• Attenuated viruses in live oral vaccine reacquire neurovirulence and transmission capacity through extended replication and genetic divergence.
• Genetic divergence exceeds 1 percent (or greater than 10 nucleotide changes) for poliovirus types 1 and 3.
• Genetic divergence exceeds 0.6 percent (or greater than 6 nucleotide changes) for poliovirus type 2.
• Mutated viruses circulate in communities for extended periods causing paralytic disease outbreaks.
• Type 2 poliovirus accounts for approximately 90 percent of all vaccine-derived outbreaks globally.

Classification Categories

Circulating Vaccine-Derived Poliovirus

• Demonstrates active person-to-person transmission within community settings.
• Requires isolation of genetically linked viruses from at least two individuals who are not household contacts.
• Alternatively diagnosed via one human isolate combined with environmental surveillance samples, or multiple distinct environmental samples.
• Capable of replicating efficiently at normal body temperature.

Immunodeficiency-Associated Vaccine-Derived Poliovirus

• Isolated exclusively from individuals possessing primary B-cell or combined immunodeficiency disorders.
• Immunocompromised state permits persistent chronic viral shedding.
• Shed viruses demonstrate regained neurovirulence over extended carriage periods.

Ambiguous Vaccine-Derived Poliovirus

• Represents clinical isolates from individuals lacking known immunodeficiency.
• Includes sewage isolates lacking identified human origins.

Risk Factors For Emergence

• Low routine immunization coverage creates significant population immunity gaps.
• Prior successful elimination of corresponding wild poliovirus serotype removes natural immunity.
• Extensive historical reliance on monovalent and bivalent oral vaccines increases population susceptibility to type 2 strains.
• Poor sanitation infrastructure facilitates unchecked fecal-oral viral transmission.
• Insensitive acute flaccid paralysis surveillance delays outbreak detection and containment.

Comparative Profile

Vaccine Complications Comparison

Feature	Vaccine-Associated Paralytic Poliomyelitis	Circulating Vaccine-Derived Poliovirus	Immunodeficiency-Associated Vaccine-Derived Poliovirus
Origin	Spontaneous mutation in single vaccinee or close contact.	Extended circulation and mutation in under-immunized community.	Chronic unchecked replication in immunodeficient host.
Transmission	Limited to immediate close contacts.	Active person-to-person community transmission.	Limited transmission, chronic individual shedding.
Genetic Drift	Minimal nucleotide changes.	>1% divergence (Types 1, 3) or >0.6% (Type 2).	Progressive divergence during chronic carriage.
Primary Serotype	Type 3 predominantly.	Type 2 predominantly (>90%).	Varies based on exposure.
Risk Factors	First vaccine dose, lack of maternal antibodies.	Low herd immunity, poor sanitation.	Primary B-cell or combined immunodeficiency.

Management And Preventive Strategies

Immunization Schedule Modifications

• Sequential administration utilizing inactivated polio vaccine followed by oral polio vaccine reduces or eliminates paralytic complication risks.
• Inactivated vaccine bypasses intestinal interference, providing systemic immunity without risk of reversion.
• World Health Organization mandates inclusion of at least one inactivated vaccine dose in all national schedules to induce baseline immunity.
• Inactivated vaccine administration prior to oral vaccine minimizes complication risks while ensuring adequate mucosal immunity to interrupt wild virus circulation.
• Intradermal fractional doses of inactivated vaccine provide dose-sparing, cost-effective alternatives yielding comparable seroconversion following two doses.

Global Endgame Interventions

• Global coordinated withdrawal of trivalent oral vaccine and cessation of type 2 oral vaccine occurred in 2016.
• Implementation of bivalent oral vaccine (types 1 and 3) targets remaining wild virus strains.
• Development and emergency deployment of novel oral poliovirus vaccine type 2 directly addresses circulating vaccine-derived outbreaks.
• Novel type 2 vaccine features genetic stabilization, significantly reducing likelihood of reversion to neurovirulent forms in low immunity settings.
• Sabin-inactivated poliovirus utilizes attenuated strains for manufacture, reducing biosafety risks and enabling affordable mass production in developing nations.
• Enhanced environmental surveillance and reverse cold chain transport of stool samples ensure rapid detection and genomic sequencing of divergent strains.